Lucy Rutten: An Important Mechanistic Insight Into Future Vaccine Safety
Lucy Rutten, Senior Scientist at Leiden University, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Proud to share our recent publication in The New England Journal of Medicine.
This international collaboration began in the early phase of investigating rare cases of vaccine-induced immune thrombocytopenia and thrombosis (VITT) following adenoviral vector–based COVID-19 vaccination.
In this study, we elucidate how antibodies initially directed against adenoviral core protein VII can, in rare instances, cross-react with platelet factor 4 (PF4), a key clotting factor, due to a specific somatic mutation (K31E) in the antibody.
These findings provide important mechanistic insight into pathogenesis and future vaccine safety.
It has been a privilege to contribute to this long-standing and highly collaborative effort.”
Title: Adenoviral Inciting Antigen and Somatic Hypermutation in VITT
Authors: Jing Jing Wang, Linda Schönborn, Theodore E. Warkentin, Luisa Müller, Thomas Thiele, Lena Ulm, Uwe Völker, Sabine Ameling, Sören Franzenburg, Lars Kaderali, Ana Tzvetkova, Alex Colella, Tim Chataway, Chee Wee Tan, Bridie Armour, Alexander Troelnikov, Lucy Rutten, James McCluskey, Roland Zahn, Tom P. Gordon, Andreas Greinacher
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 11, 2026, 17:41Khaled Musallam: Earlier Recognition, Better Outcomes in NTDT
-
Sep 11, 2026, 17:29Reyhan Kose Cobanoglu: APS ACTION Registry Study Published in Lupus
-
Sep 11, 2026, 17:14Obi Light Ogbonnia: From Kenya to Global Sickle Cell Advocacy
-
Sep 11, 2026, 17:01EAHAD 2027 Marks 20 Years
-
Sep 11, 2026, 16:54Denise Braendgaard: Reimagining Health Systems Through Collective Action
-
Sep 11, 2026, 16:47Jehad Khamaysa: Budd-Chiari Syndrome as the Initial Presentation of Behçet’s Disease in a 16-Year-Old
-
Sep 11, 2026, 16:44Mostafa Faisal Mohammed Saleh: From HLA Biology to Curative Therapy
-
Sep 11, 2026, 16:38Jim Kaveney: Class I, Level A – Lifestyle is Now the Official Standard in AFib Care
-
Sep 11, 2026, 16:31George Touma: Do We Really Need to Implant Metal in Every High-Bleeding-Risk Patient?